Erasca Receives FDA Fast Track for ERAS-0015 in Pancreatic Cancer: Phase 1 Data Shows 57% Response Rate
Market Chameleon (Mon, 24-Aug 8:51 AM)
Erasca’s $550 Million Upsized Public Offering Bolsters R&D Ambitions: What Investors Need to Know
Market Chameleon (Tue, 14-Jul 7:31 AM)
